Global Delirium Tremens (DT) Market, By Treatment (Antipsychotic Drugs, Anticonvulsants, Pain Medication, Antiarrhythmic Drugs, Diuretics), Complications (Seizures, Disorientation, Hypertension, Hyperthermia, Respiratory Failure, Aspiration Pneumonitis), End-Users (Clinics, Hospitals, Rehabilitation Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Delirium Tremens (DT) Market
Delirium tremens (DT) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.80% in the above-mentioned research forecast period. Increase in alcohol consumption and increasing prevalence of psychological diseases.
Moreover increasing number of generic medicines and government initiatives to check the excessive alcohol use also boost up the market growth. Moreover, vigorous research and development efforts and rising disposable income act as opportunity for the market growth. But, sometimes adverse effect related to the drugs, excessive use of benzodiazepines and growing suicidal tendencies among users may hamper the global delirium tremens (DT) market.
Delirium tremens disorder is associated with the excessive use of alcohol. As soon as alcohol abuse ceases delirium tremens starts just after 48 hours and has been reported to lasts for 5 days. Delirium tremens is characterized by the seizure activities, visual hallucinations, tachycardia, hyperthermia, diaphoresis, agitation profound confusion among others. The most common treatment for Delirium tremens is benzodiazepine which ranges from diazepam, lorazepam among several others. Along with these treatments gabapentin, chlordiazepoxide has also proved to relax symptoms associated with Delirium tremens. Moreover Delirium tremens disorder results in nutritional deficiencies as well that can be overcome by use of zinc, thiamine, phosphate, magnesium, folate, among other nutrients.
As per the publication of NCBI this has been reported that Delirium tremens is highly prevalent in adult men ranges from 17% of men to 36% of men and prevails for 12 month or for lifetime. The affected population demands effective treatment and hence expected to provide market with the lucrative growth.
This delirium tremens (DT) market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Delirium Tremens (DT) Market Scope and Market Size
Delirium tremens (DT) market is segmented on the basis of treatment, complications, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the delirium tremens (DT) market is segmented into antipsychotic drugs, anticonvulsants, pain medication, antiarrhythmic drugs and diuretics. Antipsychotic drugs are further sub- segmented into typical antipsychotics and atypical antipsychotics. Anticonvulsants drugs is further sub- segmented into primidone, phenobarbital, clonazepam, valproic acid, carbamazepine, phenytoin and ethosuximide. Antiarrhythmic drugs are sub segmented into amiodarone, flecainide, ibutilide, lidocaine, procainamide, propafenone, quinidine, tocainide and others. Diuretics is sub segmented into thiazide, loop, potassium sparing.
- On the basis of complications, the delirium tremens (DT) market is segmented into seizures, disorientation, hypertension, hyperthermia, respiratory failure and aspiration pneumonitis.
- On the basis of end-users, the delirium tremens (DT) market is segmented into clinics, hospitals, rehabilitation centers, others.
- On the basis of distribution channel, the delirium tremens (DT) market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Delirium Tremens (DT) Market Country Level Analysis
Delirium tremens (DT) market is analysed and market size information is provided by country, treatment, complications, end-users and distribution channel as referenced above.
The countries covered in the delirium tremens (DT) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America accounts the largest market share due to the changing lifestyles and enhanced alcohol consumption. Europe accounts the second largest market share due to increasing government initiative to ban alcohol and increasing collaboration and partnership for development of novel therapies. Asia-Pacific is expected to account for the largest market share over coming years for the delirium tremens (DT) market as China is one of the largest exporters of drugs used for treatment of delirium tremens and increasing psychological diseases.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Delirium tremens (DT) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Delirium Tremens (DT) Market Share Analysis
Delirium tremens (DT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to delirium tremens (DT) market.
The major players covered in the delirium tremens (DT) market are Lannett, polpharma, Bioindustria L.I.M., Aspen Holdings, Aspire Group, Bal Pharma Limited, Reine Life Science, SEQENS, Pfizer, Lundbeck, Genentech, USA Inc., GlaxoSmithKline Inc., Otsuka America Pharmaceutical, Inc., Johnson & Johnson Services, Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt, Aurobindo Pharma USA., aurolife, Cambrex Corporation, MODASA Pharmaceuticals Pvt. Ltd., Teva Pharmaceuticals USA, Inc., Novartis AG, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
